Werewolf Therapeutics (Werewolf Therapeutics) ROIC % : -138.20% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Werewolf Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -138.20%.

As of today (2024-05-28), Werewolf Therapeutics's WACC % is 8.56%. Werewolf Therapeutics's ROIC % is -96.42% (calculated using TTM income statement data). Werewolf Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Werewolf Therapeutics ROIC % Historical Data

The historical data trend for Werewolf Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics ROIC % Chart

Werewolf Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROIC %

-209.00

-452.38

-376.52

-208.31

-99.23

Werewolf Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROIC %	Get a 7-Day Free Trial													-121.99	-53.09	-83.61	-110.14	-138.20

Competitive Comparison of Werewolf Therapeutics's ROIC %

For the Biotechnology subindustry, Werewolf Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Werewolf Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's ROIC % falls into.

Werewolf Therapeutics ROIC % Calculation

Werewolf Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROIC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-40.503 * ( 1 - 0% )	/	( (32.366	+	49.272)	/ 2 )
=	-40.503	/	40.819
=	-99.23 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	160.245	-	11.668	-	( 129.315	-	max(0, 23.989	-	140.2	+	129.315	))
=	32.366

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	174.833	-	6.569	-	( 134.343	-	max(0, 19.378	-	138.37	+	134.343	))
=	49.272

Werewolf Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

	ROIC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-68.648 * ( 1 - 0% )	/	( (49.272	+	50.071)	/ 2 )
=	-68.648	/	49.6715
=	-138.20 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	174.833	-	6.569	-	( 134.343	-	max(0, 19.378	-	138.37	+	134.343	))
=	49.272

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	177.6	-	6.459	-	( 139.189	-	max(0, 21.214	-	142.284	+	139.189	))
=	50.071

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

Werewolf Therapeutics (NAS:HOWL) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Werewolf Therapeutics's WACC % is 8.56%. Werewolf Therapeutics's ROIC % is -96.42% (calculated using TTM income statement data).

Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Werewolf Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » ROIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472

Website

https://www.werewolftx.com

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake	officer: Chief Technology Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard	officer: Chief Operating Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc	10 percent owner	800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin	10 percent owner	6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin	director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520